CClinicalTrials.gg
CompletedNCT03049631RRB2Updated Jul 14, 2020

Red Raspberry Polyphenols on Gut Microbiome

An interventional study of Raspberry and fructooligosaccharide and Raspberry in Healthy Subjects and Pre-diabetes, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology. Completed at 1 site in United States. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-14.

Sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

The primary objective aims are to assess the effects of regular consumption of red raspberries (RRB) with and without fructooligosaccharide (FOS) on the composition of the gut microbiota after 4 week intake and in parallel characterize plasma and urine metabolite profiles examining qualitative and quantitative intervention associated changes.

Read the detailed description

The study will be performed as a single-blinded, randomized, crossover manner. Thirty subjects (20 insulin resistant subjects and 10 healthy subjects) will be randomly assigned into one of two sequences: sequence A (n=15) will be RRB then RRB+FOS (which means subject will consume only RRB (125 g/day(d) (equivalent to 1 cup fresh RRB)) with breakfast for 4 weeks, and then after a 4-week washout period, that subject will consume the RRB with FOS (125 g/d RRB and 8 g/d FOS) for 4 weeks); sequence B (n=15) will be RRB+FOS then RRB (which means subject will receive the RRB with FOS for 4 weeks, a 4-week washout, and then the RRB for another 4-week). At the beginning and end of each 4-week treatment, subjects will undergo a 6-h Study Day (4 study days in 12-week study duration) followed by a 1-h next morning follow-up visit.

Subjects will be required to meet several inclusion and exclusion criteria, which will be assessed through online survey and on-site clinic assessments, including questionnaires, blood analysis and anthropometric measures. Eligible subjects will be invited to participate in the study. Each subject will be asked to come for 1 Screening Visit, 4 dinner pick-ups (the day before each Study Day), 4 Study Days and 6 Weekly Meetings.

During the Screening Visit, subjects will read, sign and date a written Institutional Review Board approved Informed Consent Form prior to performing any study procedure. And then they will be assessed their qualification, instructed on the process for completing study questionnaires and counseled to restrict intake of colored plant foods rich in phytonutrients the 3 days prior to each Study Day. They will be asked to restrict alcohol intake, coffee/tea/ caffeinated beverage intake and moderate / vigorous physical activity and to drink plenty of water to maintain hydration in the 24 h prior to each Study Day. They will be instructed to come to the Clinical Nutrition Research Center (CNRC) the day before each Study Day to pick up their dinner meal and evening snack. Subjects will be asked to get at least 7 hours sleep and to come to the CNRC after a 10-h overnight fasting on each Study Day.

Each Study Day will require subjects to be in the clinic for \~7 h to complete all baseline and post challenge beverage testing procedures, including a 6 h study day and a 1 h next morning follow-up visit. Subjects will be evaluated for compliance with the protocol (diet, exercise, sleep, fasting), have their body weight and blood pressure measured, ingest a cup of red raspberry drink (250 g RRB (equivalent to 2 cups fresh RRB) and 64 g glucose) and their blood, urine and feces samples will be collected.

02

Conditions studied

  • Healthy Subjects
  • Pre-diabetes

Keywords

  • Pre-diabetes
  • red raspberry
  • fructooligosaccharide
  • metagenomics
  • polyphenol bioavailability
  • glycemic response
  • insulin response
03

In context

Prediabetic State

999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.

This study's enrollment of 30 is below the median of 65 across 844 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Clinical Nutrition Research Center, Illinois Institute of Technology is the lead sponsor of 59 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Non-smoking1 man or woman, 20-60 years of age, inclusive
  2. Group 1 must have a fasting blood glucose between 100-125 mg/dL and inulin ≥ 8 μIU/mL
  3. Group 2 will have a fasting blood glucose below 100 mg/dL and the homeostasis model assessment method of insulin resistance (HOMA-IR) [glucose (μmol/L) × insulin (μunits/μL)/22.5] value less than 1
  4. Judged to be in good health on the basis of the medical history
  5. Able to provide informed consent and comply with study procedures
  6. Able to comply to the study instructions (including dietary restrictions, consumption of study beverage, records of food diary and GI-tract questionnaire, sample collection procedure and study visit schedule)
  7. Able to maintain your usual physical activity pattern
  8. Able to abstain from alcohol consumption and avoid vigorous physical activity for 24 hours prior to and during study visit

Exclusion criteria

Exclusion Criteria:

  1. Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg at screening visit.
  2. Major trauma or a surgical event within 2 months or longer depending on trauma or event and after consultation with PI.
  3. Weight change ≥4.5 kg (9.9 lbs) within 2 months
  4. Presence of chronic constipation, diarrhea or other chronic gastrointestinal complaint (e.g. irritable bowel syndrome)
  5. Had gastrointestinal barium opaque meal within 3 months
  6. History or presence of clinically important endocrine, cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, or biliary that, in the opinion of the investigator, could interfere with the interpretation of the study results
  7. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer
  8. History of extreme dietary habits, as judged by the investigator (e.g., Atkins diet, etc.)
  9. History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional
  10. Vegan or other extreme dietary regimens as judged by the investigator.
  11. Has a known intolerance or sensitivity to any ingredients in the study products
  12. Has used antibiotics within the previous 2 months
  13. Has used prebiotics, probiotics, or drugs active on gastrointestinal motility, or a laxative of any class within 1 month
  14. Has used medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, hypoglycemic medications, and systemic corticosteroids within 2 weeks
  15. Female, who is pregnant, lactating or planning pregnancy during the study period
  16. Has participated in prebiotics or laxative trial within 3 months prior to enrollment or any other clinical trial within 1 month
  17. Donated blood within last 3 months
  18. Working overnight (e.g. 3rd shift)
  19. Excessive coffee and tea consumption (> 4 cups/day)
  20. Men and women who do excessive exercise regularly or athlete
  21. Men and women whom investigator is uncertain about subject's capability or willingness to comply with protocol requirement
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Raspberry and fructooligosaccharide

    Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)

    Dietary Supplement: Raspberry and fructooligosaccharide

  • Experimental
    Raspberry

    Red raspberries (1 cup equivalent)

    Dietary Supplement: Raspberry

Interventions

  • Dietary supplementRaspberry and fructooligosaccharide

    Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)

  • Dietary supplementRaspberry

    Red raspberries (1 cup equivalent)

06

What researchers measure

Primary outcomes

  1. Changes in gut microbiome composition as measured by 16S rRNA gene sequencing in 12-week intervention of active treatment vs Experimental

    gut microbiome composition changes

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

Secondary outcomes

  1. Changes in plasma red raspberry polyphenol metabolites in 12-week intervention of active treatment vs Experimental

    Plasma red raspberry polyphenol metabolites

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  2. Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs Experimental

    Plasma Insulin Sensitivity

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  3. Changes in plasma glucose response in 12-week intervention of active treatment vs Experimental

    Plasma glucose response

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  4. Changes in plasma insulin response in 12-week intervention of active treatment vs Experimental

    plasma insulin response

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  5. Changes in urine creatinine concentration in 12-week intervention of active treatment vs Experimental

    urine creatinine concentration

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  6. Changes in urine red raspberry polyphenol metabolites in 12-week intervention of active treatment vs Experimental

    urine red raspberry polyphenol metabolites

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  7. Changes in breath hydrogen exhalation in 12-week intervention of active treatment vs Experimental

    breath hydrogen exhalation

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  8. Changes in Gastrointestinal Health as measured by Gastrointestinal Tract Questionnaire in 12-week intervention of active treatment vs Experimental

    Gastrointestinal Health

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  9. Changes in blood pressure in 12-week intervention of active treatment vs Experimental

    blood pressure

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

Other outcomes

  1. Changes in body weight in 12-week intervention of active treatment vs Experimental

    body weight

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  2. Changes in waist circumference in 12-week intervention of active treatment vs Experimental

    waist circumference

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  3. Changes in plasma triglycerides in 12-week intervention of active treatment vs Experimental

    plasma triglycerides

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  4. Changes in plasma LDL cholesterol in 12-week intervention of active treatment vs Experimental

    plasma LDL cholesterol

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

  5. Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs Experimental

    plasma HDL cholesterol

    Time frame: baseline, 4 weeks, 8 weeks and 12 weeks

07

Study locations

1 site
  • Clinical Nutrition Research Center
    Chicago, Illinois 60616, United States
08

References and documents

Publications

  • Zhang X, Zhao A, Sandhu AK, Edirisinghe I, Burton-Freeman BM. Red Raspberry and Fructo-Oligosaccharide Supplementation, Metabolic Biomarkers, and the Gut Microbiota in Adults with Prediabetes: A Randomized Crossover Clinical Trial. J Nutr. 2022 Jun 9;152(6):1438-1449. doi: 10.1093/jn/nxac037. PubMed 35421233 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03049631
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Responsible party
Sponsor
First posted
Feb 10, 2017
Start date
May 18, 2017
Primary completion
Jul 6, 2020
Completion
Jul 6, 2020
Last update
Jul 14, 2020

Study contacts

Britt M Burton-Freeman, Ph.D
principal investigator · Illinois Institute of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion